Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis

@article{Serrano2013SystematicRA,
  title={Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis},
  author={Ana Julissa Serrano and Leire Bego{\~n}a and Eduardo Anitua and Raquel Victoria Jara Cobos and Gorka Orive},
  journal={Gynecological Endocrinology},
  year={2013},
  volume={29},
  pages={1005 - 1014}
}
Abstract The aim of this meta-analysis was to evaluate the efficacy and safety of two bisphosphonates (alendronate and zoledronate) in the treatment of postmenopausal osteoporosis. The incidence of fractures was considered as primary endpoint. Only randomized trials with a follow-up period of 1 year or more were included in this systematic review and meta-analysis. We excluded studies that included patients with secondary osteoporosis especially in relation to therapy with corticosteroids or… Expand
Efficacy of Bisphosphonates for Preventing Osteoporotic Fracture in Postmenopausal Women: A Systematic Review and Meta – Analysis
TLDR
Bisphosphonates were efficacious in preventing bone fractures in postmenopausal women with osteoporosis, however, studies on clodronate, etidronate and ibandronate were limited, thus further studies should be conducted. Expand
The efficacy and safety of vertebral fracture prevention therapies in post-menopausal osteoporosis treatment
TLDR
This study suggests that, taking efficacy and safety into account, parathyroid hormone and zoledronic acid had the highest probability of satisfactory performance in preventing osteoporotic fractures. Expand
The Safety of Bisphosphonates for Primary Osteoporosis: An Overview of Systematic Reviews and Meta-analysis
TLDR
An overview of systematic reviews to evaluate the risk of adverse events of BPs used in primary osteoporosis and a new meta-analysis for the primary outcomes as the conflicting results of the original systematic reviews are made. Expand
Efficacy of bisphosphonates against hip fracture in elderly patients with stroke and Parkinson diseases: meta-analysis of randomized controlled trials.
TLDR
A meta-analysis of strictly conducted RCTs suggest that there is efficacy against hip fracture with bisphosphonates treatment in patients with stroke and Parkinson disease. Expand
Safety of Bisphosphonates for Postmenopausal osteoporosis: An Overview of Systematic Reviews
TLDR
An overview of reviews to systematically evaluate the risk of adverse events (AEs) of bisphosphonates used for the treatment of postmenopausal osteoporosis indicated that bisph phosphonates significantly increased therisk of AF, sAF and stroke, but did not significantly increase the riskof atypical fracture or fracture union. Expand
Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease
TLDR
The result showed that bisphosphonates decreased bone mass density (BMD) loss at the lumbar spine, reduced the risk of new fractures, and retained the similar adverse events in patients with IBD. Expand
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis
TLDR
Zoledronate might be the best choice to increase the BMD in LS and teriparatide (20mg) might lead to the lowest fracture rate. Expand
Design of the SALT Osteoporosis Study: a randomised pragmatic trial, to study a primary care screening and treatment program for the prevention of fractures in women aged 65 years or older
TLDR
The design of the SALT Osteoporosis study, which aims to examine whether the screening and treatment of older, female patients in primary care can reduce fractures, in comparison to usual care, is described. Expand
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control
TLDR
Combining both adjusted direct comparisons and own-control analysis may provide an estimate of real-world treatment efficacy that could potentially complement clinical trial findings. Expand
A Comparative Study of the Effect of Sodium Alendronate plus Thyme and Sodium Alendronate alone in Treatment of Postmenopausal Women with Osteoporosis
TLDR
Assessment of the efficacy of sodium alendronate plus Thyme in treatment of postmenopausal women with osteoporosis found a significant increase in BMD and significant rise in t score in group treated with Sodium alendronsateplus Thyme after 6 months as compared with baseline. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 54 REFERENCES
Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women.
TLDR
Alendronate increases bone density in both early postmenopausal women and those with established osteoporosis while reducing the rate of vertebral fracture over 2-3 yr of treatment, casting doubt on traditional distinctions between osteopootic and nonosteoporotic fractures. Expand
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
TLDR
Of the five interventions reviewed, only raloxifene appeared to reduce the risk of vertebral fracture in postmenopausal women unselected for low bone mineral density (BMD). Expand
Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women
TLDR
Therapy with alendronate is associated with significant and clinically important reductions in the incidence of hip fracture in women with postmenopausal osteoporosis, and the overall reduction is consistent among different patient populations. Expand
A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group.
TLDR
The present results indicate that alendronate effectively decreases bone turnover in a dose-related manner and increases lumbar BMD at a dosage of 2.5 mg/day, the lowest dose used in this study, in Japanese patients with osteoporosis. Expand
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
TLDR
At 10 mg per day, both clinically important and statistically significant reductions in vertebral, non-vertebral, hip and wrist fractures were observed for secondary prevention andgold' level evidence, www.cochranemsk.org was found. Expand
Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
TLDR
Etidronate, at 400 mg per day, demonstrated a statistically significant and clinically important benefit in the secondary prevention of vertebral fractures in postmenopausal women. Expand
Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study
TLDR
For postmenopausal women with low bone mass, alendronate is well tolerated and produces significant, progressive increases in BMD at the lumbar spine and hip in addition to significant reduction in the risk of nonvertebral fracture. Expand
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
TLDR
Among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebra fractures, as well as other clinical fractures. Expand
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
TLDR
It is concluded that treatment with ALN over a period of 2 yr was well tolerated and produced dose-dependent increases in BMD without evidence of a plateau over the dose range of 1.0-5.0 mg daily. Expand
Zoledronic acid and clinical fractures and mortality after hip fracture.
TLDR
An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and with improved survival. Expand
...
1
2
3
4
5
...